oncoquest-cll vaccine

Oncoquest-CLL vaccine is a personalized autologous tumor vaccine developed for the treatment of chronic lymphocytic leukemia (CLL). It is manufactured using each patient's own leukemic cell lysate combined with recombinant human interleukin-2 (IL-2) and formulated in a synthetic multilamellar liposomal structure. The mechanism of action involves stimulating the patient’s immune system to recognize and attack their own leukemia cells by presenting patient-specific tumor antigens together with an immunostimulant. This approach aims to induce an effective anti-tumor immune response in treatment-naïve CLL patients, particularly those in early asymptomatic stages. The vaccine is administered subcutaneously over five sequential doses following leukapheresis for cell collection[1][2][3][5].